We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immunovant Inc (IMVT) USD0.0001

Sell:$25.86 Buy:$25.88 Change: $0.20 (0.78%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.86
Buy:$25.88
Change: $0.20 (0.78%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.86
Buy:$25.88
Change: $0.20 (0.78%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Contact details

Address:
320 West 37Th Street
NEW YORK
10018
United States
Telephone:
+1 (917) 5803099
Website:
https://immunovant.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMVT
ISIN:
US45258J1025
Market cap:
$3.85 billion
Shares in issue:
146.78 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Frank Torti
    Executive Chairman of the Board
  • Peter Salzmann
    Chief Executive Office, Director
  • Eva Barnett
    Chief Financial Officer
  • Melanie Gloria
    Chief Operating Officer
  • Jay Stout
    Chief Technology Officer
  • Julia Butchko
    Chief Development Officer
  • Michael Geffner
    Chief Medical Officer
  • William Macias
    Chief Medical Officer
  • Mark Levine
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.